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Neurofilament light in CSF and serum is
a sensitive marker for axonal white matter
injury in MS
ABSTRACT
Objective: In an ongoing, open-label, phase 1b study on the intrathecal administration of rituximab
for progressive multiple sclerosis, an intraventricular catheter was inserted for drug delivery. The
objective of this study was to characterize the limited white matter axonal injury evoked by cath-
eter insertion by analyzing a panel of markers for tissue damage in CSF and serum.
Methods: Lumbar CSF and serumwere collected before catheter insertion and at regular intervals
during the follow-up period of 1 year. Levels of neurofilament light polypeptide (NF-L), glial fibril-
lary acidic protein, microtubule-associated protein tau, and S100 calcium binding protein B were
measured in the CSF, and NF-L was also quantified in serum at each time point.
Results: One month after neurosurgical trauma, there was a distinct peak in NF-L concentration in
both CSF and serum. In contrast, the biomarkers S100 calcium binding protein B, glial fibrillary
acidic protein, and microtubule-associated protein tau did not show any significant changes.
NF-L levels in both CSF and serum peaked at 1 month post surgery, returning to baseline after
6 to 9 months. A strong correlation was observed between the concentrations of NF-L in CSF
and serum.
Conclusions: The NF-L level, in CSF and serum, appears to be both a sensitive and specific marker
for white matter axonal injury. This makes NF-L a valuable tool with which to evaluate acute white
matter axonal damage in a clinical setting. Serum analysis of NF-L may become a convenient way
to follow white matter axonal damage longitudinally.
ClinicalTrials.gov identifier: NCT01719159. Neurol Neuroimmunol Neuroinflamm2016;3:e271; doi:
10.1212/NXI.0000000000000271
GLOSSARY
EDSS 5 Expanded Disability Status Scale; GFAP 5 glial fibrillary acidic protein; IT 5 intrathecal; MS 5 multiple sclerosis;
NF-L 5 neurofilament light polypeptide; PMS 5 progressive multiple sclerosis; S100B 5 S100 calcium binding protein B;
Tau 5 microtubule-associated protein tau; tTau 5 total Tau.
Biomarkers of cell injury in the CNS are important tools to help evaluate neurologic disease pro-
cesses. The presence of elevated levels of neurofilament light polypeptide (NF-L) in the CSF is
an indicator of axonal damage in the CNS.1 However, little is known about the dynamics of this
biomarker following a damage-inducing event and how well elevated CSF NF-L levels are
mirrored in the peripheral circulation.
We have initiated a phase 1b study to investigate the safety, feasibility, and efficacy of ritux-
imab delivered intrathecally (IT) as a potential therapy in a group of patients with progressive
multiple sclerosis (PMS) not responsive to other therapies. During this study, a ventricular cath-
eter attached to an Ommaya reservoir was inserted surgically in order to secure safe delivery of
the therapeutic antibody into the CSF compartment. In our preliminary analyses, we noted
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a distinct elevation of NF-L levels at the first
CSF examination following the introduction
of the ventricular catheter.
This study thus created a system similar to
an experimental injury model, which enabled
us to explore the dynamics of NF-L levels in
CSF as a biomarker for white matter axonal
injury. To further characterize the response
to the surgical trauma, we also analyzed CSF
levels of the astrocyte markers glial fibrillary
acidic protein (GFAP) and S100 calcium
binding protein B (S100B) and the neuronal
marker microtubule-associated protein tau
(Tau). In addition, NF-L levels in serum were
quantified using a newly developed, sensitive
method and compared with the corresponding
values in CSF.
METHODS Standard protocol approvals, registrations,
and patient consents. The intrathecal therapy–PMS trial
(ClinicalTrials.gov identifier NCT01719159) is an open-label,
interventional study primarily aimed at examining the feasibility
and safety of IT administration of rituximab in PMS. Inclusion
criteria were the diagnosis of PMS and failure to respond to or being
ineligible for conventional therapies. The study was approved by
the Regional Ethical Review Board of Umeå University (Dnr
08-157M). Informed consent from each patient was obtained
before enrollment.
Patients. The study population comprised the first 12 patients
included in the trial. At inclusion, the mean age was 47.3 years
(range 31–60) and the mean disease duration was 15.3 years.
The median Expanded Disability Status Scale (EDSS) score at
inclusion was 6.5 (table 1).
Surgery. Under general anesthesia, a ventricular catheter was
introduced into the right frontal horn through a 14-mm-
diameter burr hole placed 2 cm to the right of the midline at the
level of the coronal suture and connected to a subcutaneous
Ommaya reservoir.
Clinical evaluations. Patients were evaluated clinically for pos-
sible side effects, relapses, and EDSS score at baseline and then
at 1, 3, 6, 9, and 12 months post treatment. CSF was obtained
through lumbar puncture, which was performed at each visit to
follow immunologic measures and biomarkers. MRI was per-
formed at baseline and at the 1-, 3-, 6-, and 12-month
examinations.
During the study period, no relapses were recorded but new
MRI lesions were observed in one patient. EDSS scores increased
by 0.5 in 2 patients and were stable in the remainder.
Estimation of tissue involvement of the surgical trauma.
The catheter canal was identified as a streak of no signal in
T1-weighted sagittal MRI images, leading from the cortex to
the frontal horn of the right lateral ventricle. The length of the
canal was measured with in-program tools and the thickness of
the cortex was measured in the same way, adjacent to image
artifacts caused by the Ommaya reservoir. The percentage of
white matter penetrated by the catheter was calculated. The
volume of the affected white matter was estimated based on the
known diameter of the ventricular catheter (3.1 mm).
Biomarker analysis. The concentration of NF-L in CSF was
measured using an ELISA (NF-light assay; UmanDiagnostics AB,
Umeå, Sweden) according to the ELISA kit instructions.2 The
manufacturer of the kit states the assay’s lower limit of quantification
as 32 ng/L andmean intra- and interassay coefficient of variation as 4%
and 6%, respectively.
The concentration of GFAP in CSF was measured using
an in-house ELISA based on polyclonal antibodies.3 The
assay has a lower limit of quantification of 70 ng/L and
intra- and interassay coefficients of variation of 4% and
8%, respectively.
CSF total Tau (tTau) concentration was determined using
a sandwich ELISA (Innotest hTAU-Ag; Innogenetics, Ghent,
Belgium) specifically developed to measure all Tau isoforms irre-
spective of phosphorylation status.4
S100B concentration was determined by an electrochemilu-
minescence immunoassay using a modular system and the
S100B reagent kit (Elecsys S100; Roche Diagnostics, Penzberg,
Germany).5
Serum NF-L concentration was determined using the NF-
light assay (UmanDiagnostics AB), transferred to the Simoa plat-
form using a Homebrew Kit (Quanterix Corp., Boston, MA).
The lower limit of quantification, determined by the blank mean
signal 610 SD, was 1.95 ng/L. All samples were measured in
duplicate and were well above the lower limit of quantification.
Analyses were performed by a board-certified laboratory techni-
cian using a single batch of reagents with intra- and interassay
coefficients of variation below 10% and 15%, respectively. The
method is described in detail elsewhere.6
Statistical analysis. Statistical analyses were performed in IBM
SPSS Statistics for Windows, version 23.0 (IBM Corp., Armonk,
NY). The p values were calculated using Wilcoxon signed rank
test for related samples.
Table 1 Baseline demographics of patients
included in this study
Age, y
Mean (SD) 47.3 (9.6)
Min–max 31–60
Sex, n (%)
Male 5 (42)
Female 7 (58)
Age at disease onset, y
Mean (SD) 31.9 (10.4)
Min–max 15–46
Disease duration, y
Mean (SD) 15.3 (5.5)
Min–max 6–23
EDSS score at inclusion
Median (IQR) 6.5 (6.0–7.0)
Min–max 4–7.5
CSF mononuclear cell count
Mean (SD) 2.3 (2.6)
Min–max 0–8
Abbreviations: EDSS 5 Expanded Disability Status Scale;
IQR 5 interquartile range; max 5 maximum; min 5 minimum.
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RESULTS Brain tissue injury caused by catheter
insertion. The average volume occupied by catheters
was 280 mm3 (95% confidence interval: 266–294).
Of this volume, 91.6% consisted of white matter and
8.4% of gray matter (table 2).
Release of NF-L in CSF and serum in response to brain
catheter insertion. At the 1-month follow-up after the
insertion of the ventricular catheter, we noted a distinct
elevation in NF-L concentration in CSF for all patients
compared with the baseline values taken before the
operation. NF-L levels had returned to baseline after
6 months for the majority of patients. By 12 months,
NF-L levels had returned to baseline values or below
for all patients (figure 1A). We also investigated the
corresponding presence of NF-L in serum using
a novel and highly sensitive assay, which revealed an
identical pattern of NF-L concentrations, albeit at lower
levels, also in serum (figure 1B).
The median (interquartile range) NF-L concentra-
tion in CSF increased from 409 ng/L (362–680) at
baseline to 2,460 ng/L (1,365–4,501) at 1-month
follow-up (p5 0.005). At 3-month follow-up, the value
had declined to 1,037 ng/L (636–1,463, p 5 0.007),
and at 6-month follow-up, it had further declined to
636 ng/L (443–1,080, p 5 0.041) (figure 1C). In
serum, the median (interquartile range) NF-L concen-
tration increased from 17 ng/L (14–23) at baseline to 51
Table 2 Estimation of tissue composition and volume involved by the
intraventricular catheter insertion
Gray matter White matter Total volume
No. 12 12 12
Minimum 17.4 224.2 245.3
Maximum 26.4 295.1 319.3
Mean (% of total volume) 23.6 (8.4) 256.6 (91.6) 280.1 (100)
SD 2.7 23.0 24.5
Volumes are represented in cubic millimeters.
Figure 1 Time curves for NF-L release in CSF and serum
Values in individual patients are shown in the upper panels (A and B) and as aggregated data for the whole group in the lower panels (C and D). The change
from baseline is plotted for each individual (n5 12) at the top panels (A and B) while the lower panels (C and D) display the actual values at the different time
points as boxplots indicating medians, interquartile range, and range. The time indicators for the boxplots are approximate since the intervals between the
lumbar punctures were not exactly the depicted months on the x-axis. The CSF and serum sampling occurred within 61 week for the 1-month sampling
occasion and62weeks for the other occasions. The left panels (A and C) show values from CSFwhile the right panels (B and D) show values from serum. The
p values for statistically significant changes relative to baseline are indicated. NF-L 5 neurofilament light polypeptide.
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ng/L (31–71) at 1-month follow-up (p 5 0.005),
declined to 30 ng/L (22–34) at 3-month follow-up
(p 5 0.005), and then to 21 ng/L (17–34) at
6-month follow-up (p 5 0.037) (figure 1D).
There was a strong correlation between NF-L con-
centrations in CSF and serum (R 5 0.775). NF-L in
CSF explained 59.4% (R2 5 0.601, adjusted R2 5
0.594) of NF-L in serum looking at all sampling
occasions for all patients (figure 2). In an analysis of
individual patients, the correlation between CSF and
serum was generally stronger with an R2.0.9 in 9 of
12 patients (figure e-1 at Neurology.org/nn).
Release of Tau, S100B, and GFAP in response to brain
catheter insertion. A heterogeneous response to the
insertion of the ventricular catheter was registered
for GFAP, S100B, and tTau. There were no signifi-
cant differences between the time points for CSF
sampling for any of these markers (figure 3).
DISCUSSION In this study, we show that a discrete
injury to a brain region comprised predominantly of
white matter causes a robust increase in NF-L levels
in both CSF (5-fold over baseline) and serum (3-fold
over baseline) with a predictable time course. Increases
were still evident after 3 months, but values had
generally returned to baseline at 6 months. A strong
correlation was found between CSF and serum NF-L
levels, which indicates an ongoing process of NF-L
release into the CSF that is in equilibrium with
serum. A similar pattern was not observed for
GFAP, S-100B, or tTau, indicating that the
damage to gray matter and astrocytes was insufficient
to generate a homogeneous response.
These observations were made in a phase 1b trial of
IT-administered rituximab as a potential therapy in
a group of patients with PMS who were not responsive
to other therapies. The study design included frequent
CSF sampling through lumbar punctures for an
extended follow-up period, enabling us to follow the
time courses of tissue injury biomarkers. The distinct
peak in NF-L 1 month post surgery was an unexpected
finding that prompted us to investigate whether NF-L
release was a specific response to the neurosurgical pro-
cedure. A set of biomarkers was chosen to probe both
the extent and the kinetics of the evoked damage.
However, NF-L was the only marker that displayed
a consistent pattern with levels showing an increase
in the CSF of all patients at 1-month follow-up, albeit
over a large range (,300 to.5,000 ng/L increase over
baseline; figure 1A). The surgical trauma was the only
logical explanation for the observed NF-L increase.
Previous studies have shown that NF-L release in the
CSF correlates with focal inflammatory activity in mul-
tiple sclerosis (MS).7,8 In this study, only one patient
experienced new T2 lesions and no relapses occurred
during the observation period, thus MS inflammatory
activity cannot explain the NF-L peak at the 1-month
time point. A possible factor that may contribute to the
variation in the magnitude of the response, apart from
the degree of axonal damage, is the amount of imme-
diate contact with the subarachnoid space of the indi-
vidual catheter tracts.
The average induced lesion volume corresponded
to only approximately 0.3 cm3 of brain tissue, 92%
of which was composed of white matter. This is equal
to the size of a spherical lesion with a diameter of 8 mm
and corresponds to approximately 0.25% of an average
brain volume of 1,200 cm3. The fact that we observed
a distinct and significant increase in the levels of both
CSF and serum NF-L following such a small lesion
shows that NF-L is a very sensitive marker for CNS
injury. The lack of significant or consistent responses
from the other markers tested indicates that NF-L,
which is an abundant component of nerve fiber tracts,
also appears to be specific for white matter damage. It
also agrees well with the observation that CSF NF-L is
a sensitive marker for focal inflammatory white matter
lesions in MS.7–9
Time curves of NF-L from individual patients
showed almost identical profiles in both serum and
CSF, but with much lower levels present in serum.
Of note, one patient also showed a second peak at 9
months that was mirrored precisely in CSF and serum.
Although we were not able to identify the reason for
this second peak, it provided further support that
NF-L in serum is in a continuous equilibrium with
the CSF (figure 1, A and B). Furthermore, at the
Figure 2 Correlation between concentrations of NF-L in serum and CSF
The data indicate that approximately 60% of the concentration in serum may be explained
by the concentration in CSF. NF-L 5 neurofilament light polypeptide.
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individual patient level, the correlation between NF-L
in CSF and serum reached an R2 value of.0.9 in 9 of
12 patients (figure e-1). These observations suggest
that the source of NF-L in serum is CSF rather than
effusion directly from the site of injury since one would
expect more variation between values in serum and
CSF if individual routes contributed to NF-L appear-
ance to the 2 compartments.
Previous studies have shown the potential for
serum NF-L to be an indicator of MS risk in clinically
Figure 3 Time curves for GFAP, S100B, and tTau release in CSF
Values for individual patients (A–C) and aggregated data for the whole group (D–F) are shown. The change from baseline is plotted for each individual (n512)
(A–C) while the actual values at the different time points are displayed as boxplots indicating medians, interquartile range, and range (D–F). The time
indicators for the boxplots are approximate since the intervals between the lumbar punctures were not exactly the depicted months on the x-axis. The
CSF sampling occurred within 61 week for the 1-month sampling occasion and 62 weeks for the other occasions. GFAP 5 glial fibrillary acidic protein;
S100B 5 S100 calcium binding protein B; tTau 5 total Tau.
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isolated syndrome10 and was recently reported to cor-
relate with CSF levels and MRI measures in patients
with MS.11 Our study provides further evidence for
a strong correlation between NF-L in serum and CSF
and represents an important advancement since the
analytical sensitivity of our serum assay is 25-fold
higher than previously reported.6 This facilitates the
quantification of serum NF-L in neurologically nor-
mal controls, as well as in individuals with mild
impairment,12 which was not possible before.11
Hence, serum NF-L may provide an easier and less
invasive alternative to the determination of NF-L in
CSF and gives essentially the same information.
Although we believe that our data reliably reflect
NF-L release to CSF and serum in conjunction with
small local, mainly white matter injury reliably, the
data need to be interpreted with caution. We have on-
ly examined a small number of patients with PMS.
Although the injury made by catheter insertion fol-
lowed a standardized procedure, allowing variation
of the response to a uniform lesion to be measured
with accuracy, the inflicted injury was artificial in
nature. Hence, it is perhaps not straightforward to
extrapolate these findings directly to other clinical
situations. Repeated and paired sampling in both
CSF and serum is unique and has enabled us in this
study to follow the dynamics of NF-L in both
compartments simultaneously. However, one draw-
back regarding our ability to study the dynamics of
NF-L over time was constrained by the relatively long
period from the damage-inducing event to the first
sampling occasion 1 month afterward. Thus, we can-
not determine when the peak of NF-L occurs after
a white matter lesion. From the strong correlation
between serum and CSF levels of NF-L, this question
may be resolved in future studies utilizing frequent
blood sampling in relation to known white matter
lesion–inducing events.
In this study, we report that NF-L in CSF appears
to be a sensitive and specific marker for white matter
axonal damage in the CNS. The correlation between
NF-L levels in serum and CSF shows promise for
serum NF-L as a valuable biomarker to follow the
individual dynamics of a CNS damage-inducing
event closely.
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